Agoracom Blog Home

Archive for the ‘Novamind Inc.’ Category

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, September 25th, 2021

A weekly summary of Novamind news and media, including the announcement of our inclusion in the NYSE Listed AdvisorShares Psychedelics ETF and more.

September 21, 2021

Burnout and the wounded healer​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF​

We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).

PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies. 

“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.” 

Additional information on the ETF can be found here.

September 20, 2021

Novamind to Present at Benzinga Healthcare Conference​

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

September 23, 2021

Novamind Announces DTC Eligibility for its Common Shares​

We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers. 

“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”

September 24, 2021

View all press releases

Mental Health, With a Side of Psychedelics?

A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:22 AM on Saturday, September 18th, 2021

A weekly summary of Novamind news and media, including the announcement of our selection as a research site for Karuna Therapeutics.

September 14, 2021

What Is Psycholytic Ketamine Assisted Psychotherapy?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company

The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.

Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”

September 13, 2021

View all press releases

Legalising Illicit Therapies: Why Psychedelics Could Be The Most Important Mental Health Breakthrough Of The 21st Century

As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”

The DEA Seeks To Increase Federal Production Limits For Psilocybin And Marijuana Research

In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Saturday, September 11th, 2021

A weekly summary of Novamind news and media, including the announcement of our uplisting to the OTCQB Market and much more.

September 7, 2021

Treating Trauma with Psychedelic-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.

August 31, 2021

Treating Eating Disorders with Ketamine-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Uplists to OTCQB Venture Market

We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.

“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.

September 9, 2021

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.

Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.

September 8, 2021

View all press releases

The Worldview-Changing Drugs Poised to Go Mainstream

BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.

Neurocognitive Effects of Ketamine for Depression Examined

This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”

Psychedelic Treatments Are Here, But Doctors Aren’t Prepared

Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:59 AM on Saturday, August 28th, 2021

A weekly summary of Novamind news and media

August 24, 2021

Pairing Ketamine with EMDR & Other Therapy Methods

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Bob Mcnutt to discuss how ketamine is combined with a variety of psychotherapy modalities, particularly Eye Movement Desensitization and Reprocessing (EMDR).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Peace Blockade

Erinn Baldeschwiler is just “looking for a sense of peace as she dies.” Baldeschwiler has terminal breast cancer and has tried to turn to psilocybin therapy, under the Right to Try Act, to help. But it hasn’t been that simple. It’s why she and other patients in similar situations are taking it to the courtroom. The case is set for next month, with the potential for a decision to come as early as this fall. “For Baldeschwiler, a safe and caring treatment plan involving psilocybin may be what helps her find peace. For her, now is the time to act — she doesn’t have much of it to spare.”

New UW Center to Study Emerging Field of Psychedelic Compounds for Medical Treatments

Exciting news out of Wisconsin as the Transdisciplinary Center for Research in Psychoactive Substances is announced. “Four clinical trials in phases 1 to 3 are currently underway at UW–Madison to prepare for submitting applications for new drugs to the Food and Drug Administration.” The center has stated it will seek to include more minorities and marginalized groups in their research.

Researchers Work to Integrate Psychedelic Drug and Music Therapies Using Technology

Music and psychedelics have a long history together. And now, some tech companies “are designing music to help you get the most out of your trip,” creating music to enhance the therapeutic potential of psychedelics.

Follow @novamind_inc on Instagram

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:34 AM on Saturday, August 21st, 2021

A weekly summary of Novamind news and media

August 17, 2021

Psychedelics, Psychosis, & the Abuse Potential of Ketamine

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison talk about the relationship between psychedelics and psychosis and discuss the abuse potential of ketamine.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com 

View all media

Psychedelics are getting closer to approval, but the market may not be ready

Amirah Al Idrus explores the regulatory issues facing psychedelics, the setting in which they’re administered and how traditional business models may need to evolve in the process. At Novamind, we’re building the infrastructure to expand access to psychedelics in anticipation of their FDA approval. We’ve developed and are developing psychedelic therapy protocols to target difficult-to-treat mental health conditions that are underserved by the current standard of care. You can learn more about those treatment protocols here.

We Just Got Closer to Understanding Why Ketamine Is Such a Powerful Antidepressant

We know ketamine’s power to treat depression. “Within hours, a single dose of the psychedelic substance has been shown to curb suicidal intent, and recent clinical trials suggest these effects work on two thirds of patients, lasting for up to several weeks before fading away.” But recent results are getting us closer to the scientific reason why—ketamine may be responsible for decreasing the release of glutamate in our brains. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:13 AM on Saturday, August 14th, 2021

A weekly summary of Novamind news and media, including the sale of our investment in the Synthesis Institute and much more.

OPINION August 10, 2021

Consciousness, Meaning, and the Search For Self

In this episode, Dr. Steve Thayer, Dr. Reid Robison, and Vhari Macbeth discuss the concept of the self, multiple “selves”, and how we work with “selfhood” in psychedelic therapy.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com 

View all media

Novamind Divests Non-Core Retreat Investment

Novamind has completed the sale of its investment in the Synthesis Institute, a strategic decision that enables Novamind to focus on the expansion of its network of clinics and clinical research sites located in the U.S.

“Novamind has experienced rapid growth in its two core businesses,” said Yaron Conforti, Chief Executive Officer and Director. “We’ve established a unique and scalable business model that serves clients at our clinics and drug developers at our research sites. We are now exclusively focused on the continued growth of our clinic and contract research organization businesses, with near-term expansion into other U.S. states and an exciting pipeline of clinical trials.”

August 11, 2021

View all press releases

Could Ketamine Restore Child-like Brain Plasticity and Learning?

New research indicates that ketamine, in combination with light, may be able to temporarily restore our brains back to the plasticity seen in critical growth periods. More research is needed, but initial studies are promising. “Whether or not ketamine and/or flickering light could enable temporary neural plasticity in other parts of the brain, perhaps to treat language disorders or learning disabilities, is also “an intriguing possibility and would need further experiments,” Siegert added.” We look forward to further research exploring the life changing potential of ketamine.

Tripping Together

Zoe Cormier explores the benefits and costs of psychedelic therapy models—group vs solo. Strong anecdotal evidence is provided for the group therapy model. In practice, a case can be made for both, which is why the treatment protocols available at our Cedar Psychiatry clinics include group and solo participation. You can learn more about them here.

Follow @novamind_inc on Instagram

For further information, contact:

Samantha DeLenardo
VP, Communications
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:03 AM on Saturday, August 7th, 2021

A weekly summary of Novamind news and media, including the announcement of our new VP of Communications and much more.

FEATURES August 6, 2021

A Step Forward for Mental Health

Where other treatments for depression have failed, ketamine has changed lives. Chief Medical Officer Dr. Reid Robison spoke to Leafly about how ketamine is changing mental healthcare.

“Ketamine is now emerging as a powerful catalyst to accelerate the healing and recovery process in individuals suffering from a wide array of mental health symptoms.”

OPINION August 3, 2021

Why Do We Self-Sabotage?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer, Vhari MacBeth, and Derick Moody explore the curious phenomenon of self-sabotage.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com 

FEATURES August 3, 2021

Predicting the Boom

Business insider covers our business model and why VCs are bullish on the psychedelic boom.

“2021 and the vast majority of 2022 will be laying infrastructure groundwork for the coming global industry to emerge”

View all media

Novamind Strengthens Mental Health Expertise, Adds Communications Leader

We are pleased to announce the appointment of Samantha DeLenardo as Vice President, Communications to lead Novamind’s communications, marketing and investor relations.

“At Novamind, we care deeply about the clients and families we serve,” said DeLenardo. “We are prepared to meet this transformative moment for psychedelics and mental health, thanks in large part to the courage and years of advocacy by people with lived expertise and medical practitioners. Novamind understands both the responsibility and opportunity before us, and I look forward to sharing the Company’s story with the world.”

August 6, 2021

View all press releases

Usona Institute Breaks Ground for Global Center in Psychedelic Science

In a big step forward for psychedelics, Usona Institute announced the groundbreaking of a Global Center in Psychedelic Science. The campus will “support a blend of disciplines in psychedelic science and education.” It’s another example of momentum building around the truly extraordinary therapeutic potential of psychedelics.

TheraPsil’s Proposed ‘Access to Psilocybin for Medical Purposes Regulations’

Words have not been minced. CEO Spencer Hawkswell comments on the current exemptions for the terminally ill in Canada, “We are going to be lobbying hard to get those regulations set into law to make sure that Canadians can realize their rights to psilocybin.” We look forward to that access expanding to all Canadians.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:17 AM on Saturday, July 31st, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our fifth location in Draper, Utah.

OPINION July 27, 2021

The Art and Science of Psychedelic Trip-Sitting

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.

Visit us at psychedelictherapyfrontiers.com to learn more, subscribe and catch up on previous episodes you may have missed.

FEATURES July 28, 2021

Potential for Exponential Increase in Healing

Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.

“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison

View all media

Novamind Opens 5th Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.

“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.

July 29, 2021

View all press releases

Back to the future: Psychedelic drugs in psychiatry

In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward. 

Psychedelic trips could soon be part of therapy — here’s what those sessions will look like

Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:10 AM on Saturday, July 17th, 2021

A weekly summary of Novamind news and media, including the announcement of Novamind’s selection as a research site for Bionomics’ PTSD clinical trial.

OPINION July 7, 2021

Is the Mystical Experience Necessary for Psychedelic Healing?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.

FEATURES July 7, 2021

The Future of Ketamine

Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.

“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.

View all media

Novamind Selected as Research Site for Bionomics’ PTSD Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.

“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.

July 8, 2021

View all press releases

Psychedelic Drug Psilocybin “Magic Mushrooms” Spurs Growth of Neural Connections Lost in Depression

Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly. 

Can LSD Treat Food Allergies? We Don’t Know, But It’s Already Been Patented

While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.

Follow @novamind_inc on Instagram

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, July 10th, 2021

A weekly summary of Novamind news and media, including the announcement of Novamind’s selection as a research site for Bionomics’ PTSD clinical trial.

OPINION July 7, 2021

Is the Mystical Experience Necessary for Psychedelic Healing?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.

FEATURES July 7, 2021

The Future of Ketamine

Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.

“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.

View all media

Novamind Selected as Research Site for Bionomics’ PTSD Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.

“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.

July 8, 2021

View all press releases

Psychedelic Drug Psilocybin “Magic Mushrooms” Spurs Growth of Neural Connections Lost in Depression

Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly. 

Can LSD Treat Food Allergies? We Don’t Know, But It’s Already Been Patented

While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]